Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $120 from $112 and keeps an Outperform rating on the shares. The firm says Icotyde’s approval represents a “meaningful inflection point” for the psoriasis field and validates Protagonist ‘s peptide discovery platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
- Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
- Protagonist Therapeutics price target raised to $125 from $115 at Citi
- Protagonist Therapeutics price target raised to $119 from $113 at Barclays
- Protagonist Therapeutics price target raised to $104 from $91 at Clear Street